

Session 23: Post Class tests

1. You have been asked to value a portfolio of patents that is owned by a technology company and are considering using option pricing in the endeavor. In which of the following cases is using a real options approach likely to yield a much higher value than using a discounted cash flow approach?
 - a. A viable patent with 3 years to expiration in a safe business
 - b. A viable patent with 12 years to expiration in a safe business
 - c. A non-viable patent with 1 year to expiration in a risky business
 - d. A non-viable patent with 12 years to expiration in a risky business
 - e. All of the above
 - f. None of the above
2. Assume now that you have decided to employ an option pricing approach to value a patent on a drug to treat Alzheimer's. You believe that, if the drug were introduced today, it would generate expected cash flows of \$ 150 million/year for the next 15 years, and that the cost of commercially developing the drug today is \$2 billion. If the risk free rate is 3% and the cost of capital for pharmaceutical companies is 10%, what would you use as the value of the underlying asset (S) in the option pricing model?
 - a. -\$859 million
 - b. \$250 million
 - c. \$ 1,141 million
 - d. \$1,791 million
 - e. \$2,250 million
 - f. None of the above
3. Let us assume that you value the patent to be worth \$133 million, using an option pricing model, and that you used the remaining life of the patent (which is 15 years) as the option life in your valuation. How would your assessment of the value change if you were told that a competitor is working on a close substitute to treat Alzheimer's and is planning to bring the drug to the market in 5 years?
 - a. Lower the value of the patent
 - b. Have no effect on the value of the patent
 - c. Increase the value of the patentExplain.
4. A key input into option pricing models is the expected volatility in the underlying asset's value. In valuing a Alzheimer's drug patent as an option, which of the following approaches can you use to estimate the volatility in the "underlying" asset?
 - a. A simulation of the present value of the cash flows from developing the drug today, with different assumptions about the market size and profitability
 - b. The standard deviation in the firm values of small publicly traded, pharmaceutical companies.
 - c. The implied standard deviation in the options traded on stocks of publicly traded pharmaceutical companies, funded primarily with equity.
 - d. The standard deviation in the cash flows of drugs introduced in the past

e. Any of the above